

Special Issue

Cancer Immunotherapy and Immune Related Cardiac Complications

Message from the Guest Editor

Immunotherapy has revolutionized cancer treatment and have significantly improved the clinical outcomes of patients with advanced cancers. However, immune checkpoint inhibitors (ICIs) that target PD-1 (programmed cell death protein-1), PD-L1 (programmed cell death protein ligand-1) or/and CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) are commonly associated with acute immune-mediated adverse events. Given potential fatal cardiac complications with ICIs, studies focusing on identification of prognostic markers that can help in risk stratification are encouraged.

Guest Editor

Dr. Rabea Asleh

Department of Cardiology, Hadassah University Medical Center, Ein Kerem, P.O.B. 12000, Jerusalem 9112001, Israel

Deadline for manuscript submissions

closed (31 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/69734

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).